Immutep Limited (NASDAQ:IMMP) shares plunged roughly 80% on Friday after the biotechnology company announced it would ...

February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and ...

In recent decades, lung cancer treatment has been transformed—new surgeries, new radiation techniques, and dramatically ...

Racial disparities persist in receipt of curative treatment for early-stage non-small cell lung cancer (NSCLC), according to a study published online March 2 in JAMA Network Open. Olivia F. Lynch, MD, ...

The U.S. Food and Drug Administration (FDA) declined approval of retifanlimab-dlwr for patients with metastatic non-small cell lung cancer (NSCLC) in the United States because of manufacturing ...

Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...

Brachytherapy, a form of internal radiotherapy, has emerged as a promising treatment modality for patients with non-small cell lung cancer (NSCLC). This technique involves the precise implantation of ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua® through the country’s National Health Insurance coverage.

You and your family are our top priority. At Fred Hutch Cancer Center, we offer comprehensive and compassionate care — personalized to you. You'll have access to the latest treatment options, clinical ...

The past 30 years have seen tremendous progress in our fundamental understanding of lung cancer and the development of new treatment strategies,” senior researcher Dr. Cary Gross, a professor at Yale ...